Hercules Provides $10 Million Financing to Guava Technologies
News Jan 20, 2006
"Guava Technologies sets the new 'gold standard' for cell-based research and overcomes the limitations of traditional cell analysis methods by providing personal, integrated systems that bring sophisticated cell analysis to the laboratory benchtop and individual scientist," said Kathy Conte, managing director of Hercules.
"Guava's technology offers sensitivity, accuracy and a variety of applications but in a form that is ultra-compact, affordable, easy-to-operate and uses low sample volumes."
"In addition, Guava's technology generates 500 times less waste, and provides rapid, intuitive and easy-to-read results."
"The use of the Guava PCA systems leads to better, faster decision making, resulting in lower research and production costs."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.